Company Overview and News

 
Eicher Motors Limited - Analysts/Institutional Investor Meet/Con. Call Updates

14h nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
505200 ECQRY EICHERMOT

 
Eicher Motors Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-09-20 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
505200 ECQRY EICHERMOT

4
Flagging JLR sales dent Tata Motors m-cap; Mahindra, Bajaj Auto, Eicher zoom past

2018-09-19 moneycontrol
Jaguar Land Rover is proving to be a drag on Tata Motors' financials, so much that N Chandrasekaran-led carmaker's market capitalisation currently is even lesser than that of two-wheeler companies Bajaj Auto and Eicher Motors.
BAJAJ-AUTO 505200 ECQRY 532977 500570 TATAMOTORS EICHERMOT TTM

 
Eicher Motors Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-09-19 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
505200 ECQRY EICHERMOT

 
Nifty likely to remain under pressure; United Breweries among top 5 stocks to buy for up to 17% return

2018-09-18 moneycontrol
For third consecutive Monday, the market witnessed a negative start to the week on trade wars tension and weakness in rupee. Government measures announced over the weekend arrested the currency decline but failed to enthuse the markets.
505200 ECQRY TORNTPHARM TQRRY UBL 500420 UBHOLDINGS 507458 UNBWY EICHERMOT 532478

 
Eicher Motors Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-09-18 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
505200 ECQRY EICHERMOT

 
D-Street Buzz: PSU banks drag as BoB falls 2%; Weak rupee helps IT stocks gain led by Mindtree

2018-09-17 moneycontrol
The Indian stock market are trading on a weak note this Monday morning with the Nifty50 down 110 points and is trading at 11,404 while the Sensex is trading lower by 361 points at 37,729.
IOC 500325 500820 500547 533271 RELIANCE TCHQY 532538 ASHOKA 532755 ASIANPAINT 535789 505200 532461 INOXWIND RIGD UCLQY JSL EICHERMOT UNIVCABLES RLNIY 504212 SBAZ ECQRY UBNC BPCL 532508 IDKQY CANFINHOME UCLQF 511196 530965 ULTRACEMCO TECHM IBULHSGFIN PNJZY BRQPY PNB HINDPETRO 500104 539083

 
Eicher Motors Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-09-11 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
505200 ECQRY EICHERMOT

14
Make in India finds a smooth ride in auto industry

2018-09-11 moneycontrol
Prime Minister Narendra Modi's Make-in-India call has probably found more takers in the auto industry than any other, and perhaps accomplished in the mission's truest sense -- targeting global markets. Bajaj Auto, TVS Motor Company, Eicher Motors, Daimler, Volvo and General Motors have made India a production base for making vehicles and engines exclusively for the export markets.
BAJAJ-AUTO ECQRY TVSMOTOR 532977 DDAIF 505200 532343 GM EICHERMOT

 
Eicher Motors Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-09-07 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
505200 ECQRY EICHERMOT

 
D-Street Buzz: IT, pharma stocks rise led by Wipro, Dr Reddy#39;s Labs; Network18 zooms 15%

2018-09-03 moneycontrol
The Indian market is trading on a handsome note this Monday morning with the Nifty50 up 32 points at 11,712 while the Sensex is trading higher by 124 points at 38,769.
EKC BAJAJ-AUTO TCHQY 532977 532755 CADILAHC 505200 532321 532684 500477 500493 EICHERMOT BHARATFORG ASHOKLEY EXIDEIND ECQRY 517354 HINDALCO HVLQY ALBERTDA AKLD CDLYY TECHM HNDNF EXQDY 524075 GAMMONIND HAVELLS 509550 GOODRICKE 500086 AKLS 500440 500166

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...